Combination drug
AssigneeChugai Seiyaku Kabushiki Kaisha
InventorKo FURUGAKI
Life of this patent
Estimating the term…
Abstract
The present invention relates to a drug for treating or preventing ALK fusion gene-positive cancer positive for FGFR1 expression and positive for FGF2 expression at baseline, the drug comprising a compound having ALK inhibitory activity and a FGFR inhibitor in combination, a combination agent, a pharmaceutical composition, a preparation, a treatment or prevention method, or a drug for suppressing acquisition of resistance, a method for selecting a patient, and the like.
Claims9
-12. (canceled)
A method for selecting a patient with ALK fusion gene-positive cancer positive for FGFR1 expression and positive for FGF2 expression at baseline, the method comprising acquiring a tumor tissue of a patient diagnosed as ALK fusion gene-positive cancer, measuring expression levels of FGFR1 and FGF2 in the tumor tissue specimen, and if the patient is positive for FGFR1 expression and positive for FGF2 expression at baseline, then administering to said patient a pharmaceutical product comprising an ALK inhibitor and a FGFR inhibitor as a single composition or as separate compositions.
A pharmaceutical product for treating ALK fusion gene-positive cancer positive for FGFR1 expression and positive for FGF2 expression at baseline comprising an ALK inhibitor and a FGFR inhibitor as a single composition or as separate compositions.
Dependencies are inferred from the claim text.